Exagen Q1 2024 GAAP EPS $(0.19) Beats $(0.36) Estimate, Sales $14.415M Beat $13.095M Estimate
Exagen Q1 2024 GAAP EPS $(0.19) Beats $(0.36) Estimate, Sales $14.415M Beat $13.095M Estimate
Exagen 2024年第一季度GAAP每股收益美元（0.19美元）超過預期（0.36美元），銷售額爲1441.5萬美元，超過預期的1,309.5萬美元
Exagen (NASDAQ:XGN) reported quarterly losses of $(0.19) per share which beat the analyst consensus estimate of $(0.36) by 47.22 percent. This is a 56.82 percent increase over losses of $(0.44) per share from the same period last year. The company reported quarterly sales of $14.415 million which beat the analyst consensus estimate of $13.095 million by 10.08 percent. This is a 28.36 percent increase over sales of $11.230 million the same period last year.
Exagen（納斯達克股票代碼：XGN）公佈的季度虧損爲每股0.19美元，比分析師普遍預期的0.36美元（0.36美元）高出47.22％。這比去年同期每股虧損0.44美元（0.44美元）增長了56.82％。該公司公佈的季度銷售額爲1441.5萬美元，比分析師普遍預期的1,309.5萬美元高出10.08％。這比去年同期的112.30萬美元的銷售額增長了28.36％。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。